Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Orforglipron · Foundayo, LY-3502970

Small molecule · Agonist of GLP-1 receptor (GLP1R) · developed by Eli Lilly And Co

Approved FDA, Apr 2026
LLY Developer
1 Registered trials

What is Orforglipron?

Orforglipron is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. It acts on GLP-1 receptors in brain regions that regulate appetite and food intake, and is studied in type 2 diabetes and related metabolic conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Foundayo, LY-3502970
Drug type
Small molecule
Targets
GLP-1 receptor (GLP1R)
Mechanism
Agonist of GLP-1 receptor (GLP1R)
Pathways
appetite and caloric intake regulation
Therapy area
Endocrine, Metabolic
Developer
Eli Lilly And Co (LLY)
FDA status
Approved as Foundayo (April 1, 2026), NDA220934 · FDA label
UNII
7ZW40D021M

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 29, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07613307 Phase 3 Diabetes Mellitus, Type 2 Recruiting LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

BehaviorDiabetes MelletusDiabetes Mellitus, Type 2Endocrine System DiseasesFastingFeeding BehaviorGlucagon-Like Peptide ReceptorsGlucagon-Like Peptide-1 ReceptorGlucose Metabolism DisordersMembrane ProteinsMetabolic DisordersNutritional and Metabolic DiseasesProteinsReceptors, Cell Surface

Other drugs acting on GLP1R

Dulaglutide FDA approved Semaglutide FDA approved Tirzepatide FDA approved Avexitide Phase 3 Maridebart Cafraglutide Phase 3 VK2735 Investigational

More from Eli Lilly And Co

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3 Clazakizumab Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Orforglipron

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.